StemCells Seeks $20M in Stock Placement with Investors | GenomeWeb

NEW YORK (GenomeWeb) – StemCells today said that it intends to place common stock and warrants with two institutional investors with the aim of raising $20 million in gross proceeds.

The Newark, Calif.-based developer of stem cell therapies and research tools said that the offer includes the sale of around 11.3 million shares of common stock and short-term warrants for the purchase of up to an additional 9.6 million shares of common stock. It didn't name the two institutional investors.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nucleic Acids Research this week: ProTraits includes genetic, phenotypic data on bacteria, archaea; Candida albicans assembly 22; and more.

The Wall Street Journal reports that researchers are looking beyond Cas9 for CRISPR editing.

Familial DNA searches in criminal cases are winning over some critics, the Los Angeles Times reports.

In PNAS this week: miR-515 levels higher in women with preeclampsia, horizontal gene transfer in parasitic plants, and more.